News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02
Apr 8, 2024, 16:01

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“Trastuzumab Deruxtecan now FDA approved for pan-tumor with HER2 IHC3 and solid tumors who have received prior systemic treatment and have no alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

  • Dose 5.4 mg/kg
  • Common AE: fatigue, decreased counts and nausea. ILD can be fatal.”

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Source: Rahul Gosain/LinkedIn

cancer DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 fatigue FDA HER2 IHC3 nausea OncoDaily Oncology pan-tumor Rahul Gosain solid tumors TDxd Trastuzumab deruxtecan
Special Coverage
Insight
Feb 21, 2025, 11:40
Zoë Mullan: The launch of our much-anticipated Commission on medical oxygen security
Science
Feb 21, 2025, 11:36
Myeloma Paper of the Day, February 21st, suggested by Robert Orlowski
Dialogues
Feb 21, 2025, 11:29
HPV Self-Collection for Cervical Cancer: Dr. Kay's Insights
Science
Feb 21, 2025, 11:03
George Vlachogiannis: A growing CRC burden among younger individuals in high socio-demographic index regions
Blog
Feb 21, 2025, 11:02
Divya Sachdev: Building a future where every child, no matter where they live, has a fair chance at survival
Blog
Feb 21, 2025, 10:55
Giuseppe Curigliano: Mourning the untimely passing of Giovanni Scambia - a visionary leader in European gynecologic oncology
Blog
Feb 21, 2025, 10:45
Saurabh Zanwar: Clonal plasma cell proportion in the S-phase in multiple myeloma
Blog
Feb 21, 2025, 10:37
Cihangir Akyol: A comprehensive review on colorectal ESD outcomes by Lumir Kunovsky
Celebrities
Feb 21, 2025, 10:28
In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer
Science
Feb 21, 2025, 10:07
Elai Davicioni: Predicting Dose-Response to Prostate Cancer Radiotherapy
Blog
Feb 21, 2025, 10:00
Alexios Matikas: Adjuvant endocrine treatment strategies for non-metastatic breast cancer
Blog
Feb 21, 2025, 09:58
Miriam Mutebi: February - a whirlwind of learning, collaboration, and action